Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyle M Kampman

Showing results (61-70 of 85) with videos related to

Pageof 9
Sort By:
Neuromodulation : Journal of the International Neuromodulation Society|February 7, 2022
Deep Brain Stimulation Compared With Contingency Management for the Treatment of Cocaine Use Disorders: A Threshold and Cost-Effectiveness AnalysisFiene Marie Kuijper, Uma V Mahajan, Seul Ku, et al.
Neuroscience Letters|May 12, 2009
Association analysis between polymorphisms in the conserved dopamine neurotrophic factor (CDNF) gene and cocaine dependenceFalk W Lohoff, Paul J Bloch, Thomas N Ferraro, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 4, 2014
Nipping cue reactivity in the bud: baclofen prevents limbic activation elicited by subliminal drug cuesKimberly A Young, Teresa R Franklin, David C S Roberts, et al.
Neuroscience Letters|February 23, 2010
Association analysis between polymorphisms in the dopamine D2 receptor (DRD2) and dopamine transporter (DAT1) genes with cocaine dependenceFalk W Lohoff, Paul J Bloch, Rachel Hodge, et al.
Neuroscience Letters|September 25, 2012
Neuronal calcium sensor-1 and cocaine addiction: a genetic association study in African-Americans and European AmericansPushpinder K Multani, Toni-Kim Clarke, Sneha Narasimhan, et al.
Addiction (Abingdon, England)|September 17, 2011
Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysisJames H Stephen, Casey H Halpern, Cristian J Barrios, et al.
Neuroscience Letters|March 5, 2013
Low frequency genetic variants in the μ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaineToni-Kim Clarke, Richard C Crist, Kyle M Kampman, et al.
The Pharmacogenomics Journal|October 29, 2018
Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorderRichard C Crist, Karran A Phillips, Melody A Furnari, et al.
Alcoholism, Clinical and Experimental Research|June 11, 2008
A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial interventionDavid W Oslin, Kevin G Lynch, Helen M Pettinati, et al.
Annals of Human Genetics|December 24, 2013
The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addictionToni-Kim Clarke, Amy R D Weiss, Thomas N Ferarro, et al.
Pageof 9

Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Neuromodulation : Journal of the International Neuromodulation Society|February 7, 2022
Deep Brain Stimulation Compared With Contingency Management for the Treatment of Cocaine Use Disorders: A Threshold and Cost-Effectiveness AnalysisFiene Marie Kuijper, Uma V Mahajan, Seul Ku, et al.
Neuroscience Letters|May 12, 2009
Association analysis between polymorphisms in the conserved dopamine neurotrophic factor (CDNF) gene and cocaine dependenceFalk W Lohoff, Paul J Bloch, Thomas N Ferraro, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 4, 2014
Nipping cue reactivity in the bud: baclofen prevents limbic activation elicited by subliminal drug cuesKimberly A Young, Teresa R Franklin, David C S Roberts, et al.
Neuroscience Letters|February 23, 2010
Association analysis between polymorphisms in the dopamine D2 receptor (DRD2) and dopamine transporter (DAT1) genes with cocaine dependenceFalk W Lohoff, Paul J Bloch, Rachel Hodge, et al.
Neuroscience Letters|September 25, 2012
Neuronal calcium sensor-1 and cocaine addiction: a genetic association study in African-Americans and European AmericansPushpinder K Multani, Toni-Kim Clarke, Sneha Narasimhan, et al.
Addiction (Abingdon, England)|September 17, 2011
Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysisJames H Stephen, Casey H Halpern, Cristian J Barrios, et al.
Neuroscience Letters|March 5, 2013
Low frequency genetic variants in the μ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaineToni-Kim Clarke, Richard C Crist, Kyle M Kampman, et al.
The Pharmacogenomics Journal|October 29, 2018
Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorderRichard C Crist, Karran A Phillips, Melody A Furnari, et al.
Alcoholism, Clinical and Experimental Research|June 11, 2008
A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial interventionDavid W Oslin, Kevin G Lynch, Helen M Pettinati, et al.
Annals of Human Genetics|December 24, 2013
The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addictionToni-Kim Clarke, Amy R D Weiss, Thomas N Ferarro, et al.
Pageof 9